Walker Neal's Form 4 filing
Aclaris Therapeutics, Inc. (ACRS) · filed Feb 3, 2023
- Accession no.
- 0001209191-23-007032
- Filed
- Feb 3, 2023
- Trade date
- Feb 1-2, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market sales total $500.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Walker NealCIK 0001604457 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2023 | Common Stock | SSaleDisposed | −25,000 | $16.75 | −$418,750 | 1,180,763 | Direct | |
| Feb 2, 2023 | Common Stock | SSaleDisposed | −1,079 | $14.57 | −$15,721.03 | 1,179,684 | Direct | |
| Feb 2, 2023 | Common Stock | SSaleDisposed | −600 | $15.55 | −$9,330 | 1,179,084 | Direct | |
| Feb 2, 2023 | Common Stock | SSaleDisposed | −3,121 | $16.88 | −$52,682.48 | 1,175,963 | Direct | |
| Feb 2, 2023 | Common Stock | SSaleDisposed | −200 | $17.54 | −$3,508 | 1,175,763 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.